Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Hair and nail conditions can stabilize or improve over time, and new treatments show promise.

This review discusses the evolving understanding of frontal fibrosing alopecia as a generalized skin condition with diverse manifestations, and reports no new clinical results.

In this narrative review, researchers evaluated existing literature on the treatment of frontal fibrosing alopecia, finding that while no curative treatment exists, clinical improvements can be achieved through personalized and combined therapy approaches.

Lichen planopilaris and frontal fibrosing alopecia are likely the same disease with different clinical appearances.

This study reviewed 18 postmenopausal women with frontal fibrosing alopecia, noting frontotemporal hairline recession and eyebrow loss, often treated with steroids, triamcinolone, and other medications.

This review discusses the unique clinical features, challenges in diagnosis, and treatment protocols of frontal fibrosing alopecia in men, noting the overlap with other types of alopecia and the need for further studies.

This study suggests that vitamin D deficiency is likely not involved in the development of frontal fibrosing alopecia, as patients showed similar vitamin D levels to those with female pattern hair loss.

In this retrospective study, researchers at a Spanish hospital found that the severity of frontal fibrosing alopecia, primarily affecting postmenopausal women, was correlated with the duration of the disease, though inflammatory signs were not linked with its progression.

This case report suggests that identifying hyperpigmentation on the upper eyelid with specific dermoscopy patterns could help diagnose facial lichen planus pigmentosus without needing a facial biopsy.

This review discusses how JAK inhibitors, like tofacitinib and baricitinib, show promise in improving conditions like lichen planopilaris and frontal fibrosing alopecia by reducing severity scores and enhancing hair regrowth, though further research on safety and personalized approaches is needed.

In this study, LED therapy for eyebrow loss in older females with frontal fibrosing alopecia significantly increased eyebrow hair count after 10 treatments and maintained improvement at 6 months, indicating it could be a promising and well-tolerated treatment option.

Treating primary cicatricial alopecia is difficult and requires evidence-based methods.

This study evaluates the effectiveness of hydroxychloroquine in treating lichen planopilaris, suggesting varying success based on a real-life retrospective analysis.

In this study, both finasteride and hydroxychloroquine were found to be equally effective, safe, and well-tolerated first-line treatments for frontal fibrosing alopecia in female patients, with no significant differences in efficacy between the two therapies over six months.

Some types of hair loss can be reversed, others are permanent, and treatments vary by type.

In this study of 40 dermatomyositis patients, most with moderate-severe disease at baseline improved over time in a polyphasic pattern, while those with mild disease often remained stable.

This review discusses the enigmatic nature of frontal fibrosing alopecia and reports no clinical results; the authors stress the need for further research.

This review discusses various therapeutic options for frontal fibrosing alopecia and highlights the need for more research, as existing data are largely retrospective and lack precise treatment guidelines.

This review analyzed the use of 5-alpha reductase inhibitors (5ARIs) for treating various dermatological conditions such as androgenetic alopecia, acne, and hirsutism, emphasizing their efficacy and safety profile.

This report describes a case where a woman with frontal fibrosing alopecia initially presented with symptoms resembling rosacea, but further investigation led to a diagnosis of FFA, resulting in a treatment change to oral finasteride and hydroxychloroquine.

This review reported that 5-alpha-reductase inhibitors were effective in stabilizing disease progression or reducing the rate of progression in some cases of frontal fibrosing alopecia, though evidence on safety remains limited.

In this study, intralesional triamcinolone acetonide injections were associated with halting the progression of frontal fibrosing alopecia in female patients and showed minimal adverse effects, but the efficacy as sole therapy remains unclear pending further trials.

This review describes distinct trichoscopic findings for various alopecias in individuals with skin of color, but reports no new clinical results.

This study involved 69 hair experts using a Delphi process to achieve consensus on treating frontal fibrosing alopecia, finding strong agreement on disease monitoring but less on physical and systemic therapies, indicating the need for more research.

This narrative review suggests a strong association between abrupt hormonal imbalances and frontal fibrosing alopecia in women, especially related to reduced fertile years and certain hormonal therapies.

In this study, sensitization to ethylhexyl salicylate was found in 27.3% of patients with frontal fibrosing alopecia, suggesting it may be a potential contact allergen for this condition.

Lichen planopilaris and frontal fibrosing alopecia are likely distinct diseases with different tissue involvement.

In this study of a Colombian sample, the researchers found that while sex, alopecia location, and symptoms aligned with global reports, age at presentation, tobacco use, and use of wigs and dyes were different from those noted in other countries.

In this clinical trial, 16 women with frontal fibrosing alopecia experienced significant improvements in hair density, vellus hair count, and quality of life after monthly intralesional dutasteride treatments, though larger and longer-term studies are needed to confirm these findings.

Results are not reported in this source. The abstract does not provide a summary or findings from the Australasian Journal of Dermatology regarding contact dermatitis.